{"id":71975,"date":"2026-08-07T21:12:01","date_gmt":"2026-08-07T13:12:01","guid":{"rendered":"https:\/\/flcube.com\/?p=71975"},"modified":"2026-08-07T21:12:02","modified_gmt":"2026-08-07T13:12:02","slug":"carsgen-therapeutics-secures-nmpa-clinical-trial-approval-for-allogeneic-car-t-therapy-ct1190b-in-relapsed-refractory-large-b-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71975","title":{"rendered":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CARsgen Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2171:HKG\">HKG: 2171<\/a>) announced that its <strong>allogeneic CAR-T cell therapy CT1190B<\/strong> has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of patients with <strong>relapsed\/refractory large B-cell lymphoma (R\/R LBCL)<\/strong> who have failed at least second-line standard therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CT1190B (allogeneic CD19\/CD20-targeted CAR-T cell therapy)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory large B-cell lymphoma post-second-line therapy failure<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>August 7, 2026<\/td><\/tr><tr><td><strong>Platform Technology<\/strong><\/td><td>THANK-u Plus allogeneic CAR-T platform<\/td><\/tr><tr><td><strong>Current Trials<\/strong><\/td><td>Investigator-initiated trials (IIT) ongoing for relapsed\/refractory B-cell non-Hodgkin&#8217;s lymphoma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technological-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Technological Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapy Type:<\/strong> <strong>Allogeneic<\/strong> (off-the-shelf) CAR-T cell therapy<\/li>\n\n\n\n<li><strong>Targets:<\/strong> Dual targeting of <strong>CD19<\/strong> and <strong>CD20<\/strong> antigens<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Developed using CARsgen&#8217;s proprietary <strong>THANK-u Plus platform<\/strong><\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Preclinical to Phase 1 transition with NMPA clinical trial approval secured<\/li>\n\n\n\n<li><strong>Therapeutic Differentiation:<\/strong> Addresses critical unmet need in patients who fail multiple lines of standard therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-significance-amp-unmet-medical-need\" class=\"wp-block-heading\">Clinical Significance &amp; Unmet Medical Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Large B-cell lymphoma represents the most common form of non-Hodgkin&#8217;s lymphoma, with approximately 30-40% of patients experiencing relapse or refractory disease after initial treatment. Patients who fail second-line therapy face limited options and poor prognosis, with median overall survival often measured in months rather than years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CT1190B&#8217;s allogeneic nature represents a significant advancement over autologous CAR-T therapies, which require complex manufacturing processes using the patient&#8217;s own cells and can take weeks to produce. The &#8220;off-the-shelf&#8221; approach enables immediate treatment availability, potentially improving outcomes for rapidly progressing patients who cannot wait for autologous product manufacturing.<\/p>\n\n\n\n<h2 id=\"h-strategic-market-positioning\" class=\"wp-block-heading\">Strategic Market Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated 8,000-12,000 annual R\/R LBCL cases in China requiring third-line or later therapy<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Dual CD19\/CD20 targeting may reduce antigen escape resistance mechanisms observed with single-target CAR-T therapies<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> THANK-u Plus platform demonstrates CARsgen&#8217;s leadership in allogeneic CAR-T technology development<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Strong foundation for international regulatory submissions based on robust preclinical data<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Complements CARsgen&#8217;s existing autologous CAR-T portfolio with differentiated allogeneic approach<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy-amp-commercial-outlook\" class=\"wp-block-heading\">Development Strategy &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The ongoing investigator-initiated trials (IIT) for relapsed\/refractory B-cell non-Hodgkin&#8217;s lymphoma provide valuable real-world data to inform the formal clinical development program. This dual-track approach accelerates learning while maintaining regulatory compliance for the formal NMPA-approved trial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Allogeneic CAR-T therapies represent the next frontier in cellular immunotherapy, with potential to transform treatment paradigms by eliminating manufacturing delays, reducing costs, and expanding access to life-saving therapies for patients with aggressive hematological malignancies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for CT1190B. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and manufacturing challenges inherent in cellular therapy development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700076_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080700076_c.\"><\/object><a id=\"wp-block-file--media-e028d509-f023-45d7-a4fa-c8974ea315db\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700076_c.pdf\">2026080700076_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700076_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e028d509-f023-45d7-a4fa-c8974ea315db\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,379,62,1188],"class_list":["post-71975","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-carsgen-therapeutics","tag-clinical-trial-approval-initiation","tag-hkg-2171"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL) who have failed at least second-line standard therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71975\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma\" \/>\n<meta property=\"og:description\" content=\"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL) who have failed at least second-line standard therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71975\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T13:12:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-07T13:12:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\\\/Refractory Large B-Cell Lymphoma\",\"datePublished\":\"2026-08-07T13:12:01+00:00\",\"dateModified\":\"2026-08-07T13:12:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CARsgen Therapeutics\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2171\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71975#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71975\",\"name\":\"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\\\/Refractory Large B-Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-07T13:12:01+00:00\",\"dateModified\":\"2026-08-07T13:12:02+00:00\",\"description\":\"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed\\\/refractory large B-cell lymphoma (R\\\/R LBCL) who have failed at least second-line standard therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71975\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71975#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\\\/Refractory Large B-Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL) who have failed at least second-line standard therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71975","og_locale":"en_US","og_type":"article","og_title":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma","og_description":"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL) who have failed at least second-line standard therapy.","og_url":"https:\/\/flcube.com\/?p=71975","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-07T13:12:01+00:00","article_modified_time":"2026-08-07T13:12:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71975#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71975"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma","datePublished":"2026-08-07T13:12:01+00:00","dateModified":"2026-08-07T13:12:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71975"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CARsgen Therapeutics","Clinical trial approval \/ initiation","HKG: 2171"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71975#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71975","url":"https:\/\/flcube.com\/?p=71975","name":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-07T13:12:01+00:00","dateModified":"2026-08-07T13:12:02+00:00","description":"CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL) who have failed at least second-line standard therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71975#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71975"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71975#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed\/Refractory Large B-Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71975"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71975\/revisions"}],"predecessor-version":[{"id":71978,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71975\/revisions\/71978"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}